Pub. Date : 2016 Jun
PMID : 27143148
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | PURPOSE: Patients with unresectable wild-type KRAS metastatic colorectal cancer benefit from fluoropyrimidines (FP), oxaliplatin (O), irinotecan (I), bevacizumab (Bev), and epithelial growth factor receptor inhibitors (EGFRI). | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |